The Billion-Dollar Biotech Lie: Why Chasing Blockbusters is Killing Pharma
AstraZeneca’s pipeline struggles reveal a terrifying truth about pharma: chasing high-risk blockbusters without diversification is a recipe for systemic collapse. The real failure isn’t bad science—it’s toxic incentive structures that misalign R&D with market realities.